Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2017

View Archived Issues

NIAID begins phase I study of mosquito-borne disease vaccine candidate

FDA issues complete response letter for Amphastar's intranasal naloxone

Affigen closes series A financing to support development of cancer immunotherapies

Truxima becomes the first biosimilar MAb in oncology to be granted E.U. marketing authorization

BIIB-076 enters phase I study for Alzheimer's disease

RON kinase, a potential new therapeutic target for cancer-induced bone destruction and osteoporosis

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

FDA approves Revlimid as maintenance therapy in multiple myeloma after autologous HSCT

Phase IIa data for GSK-2330672 in patients with primary biliary cholangitis with pruritus

Prometic Life Sciences reports results from phase II study of PBI-4050 in IPF

UB-421 monotherapy shows promise for HAART substitution

ImmusanT completes phase Ib study of Nexvax2

Kalytera Therapeutics reports phase IIa results for cannabidiol in GvHD

IMDC recommends discontinuation of ADAPT trial of rocapuldencel-T

Auris Medical extends collaboration with King's College London

Revive Therapeutics and InMed in term sheet agreement for cannabinoid therapies for kidney diseases

Phytecs and Yissum Research Development establish partnership

University of South Australia patents CDK4/cyclin D1 and/or CDK6/cyclin D3 inhibitors

FDA grants priority review to Zykadia sNDA for first-line treatment of ALK-positive NSCLC

NEOMED Institute discovers new bromodomain-containing protein 4 inhibitors

Achaogen announces milestone in development of plazomicin TDM assay

Sanofi launches Mozobil in Japan

NIH leads phase I study of DS-Cav1 vaccine for RSV

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...